SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2017 / Cilt: 26 - Sayı: 1

The Effect of Low FT3 Level on Kidney Disease Progression and Potassium Levels in Euthyroid Adult Patients with Solitary Kidney

Tek Böbrekli Erişkin Hastalarda Düşük Serbest T3 Seviyesinin Böbrek Hastalığı İlerlemesine ve Potasyum Seviyesine Etkisi

Erhan TATAR
Adam USLU
Mehmet ÇALAN
Çetin İMAMOĞLU
Gökalp OKUT
Mehmet ATAKAYA
Emine ÖZAY
Kerime Rumeysa SARI
Merve UÇAR
Pages
86–92
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with a progressive course had lower FT3 levels (2.71 ± 0.34 vs. 3.17±0.47; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The aim of this study was to investigate the effect of low FT3 levels on CKD progression and hyperkalemia in euthyroid patients with solitary kidney.MATERIAL and METHODS: Seventy-six solitary kidney outpatients were enrolled in the study.
📊
Key Findings & Data:Serum Thyroid hormones (TSH, FT3 and FT4) were measured at baseline.
💡
Conclusion & Impact:Patients with a progressive course had lower FT3 levels (2.71 ± 0.34 vs. 3.17±0.47; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The aim of this study was to investigate the effect of low FT3 levels on CKD progression and hyperkalemia in euthyroid patients with solitary kidney.MATERIAL and METHODS: Seventy-six solitary kidney outpatients were enrolled in the study. Patients with a preexisting thyroid disease were excluded. The baseline and final laboratory parameters were evaluated. Serum Thyroid hormones (TSH, FT3 and FT4) were measured at baseline. RESULTS: The mean age of the patients was 50.4 ± 13.8 years and mean follow-up was 43 ± 29 months. Of the patients, 24% had progressive CKD and 19.7% developed hyperkalemia. Patients with a progressive course had lower FT3 levels (2.71 ± 0.34 vs. 3.17±0.47; p

Özet

AMAÇ: Çalışmanın amacı ötiroid soliter böbrekli hastalarda düşük serbest T3 seviyelerinin, KBH ilerlemesi ve hiperkalemi üzerine etkilerini incelemektir. GEREÇ ve yÖNTEMLER: Poliklinikte izlenen 76 tek böbrekli erişkin hasta çalışmaya dahil edildi. Tiroid hastalığı olanlar çalışma dışı bırakıldı. Başlangıç ve son kontrol laboratuvar sonuçları değerlendirildi. Tiroid hormon testlerine (TSH, sT4 ve sT3) başlangıçta bakıldı. BULGULAR: Hastaların yaş ortalamaları 50,4±13,8 yıl ve ortalama takip süresi 43±29 aydı. Hastaların %24'de KBH'da ilerleme ve %19,7'de hiperkalemi gelişti. KBH'da ilerleme gösteren hastalarda sT3 seviyeleri daha düşüktü (2,71±0,34 vs. 3,17±0,47; p

🔖

Cite This Article

TATAR, E., USLU, A., ÇALAN, M., İMAMOĞLU, Ç., OKUT, G., ATAKAYA, M., ÖZAY, E., SARI, K. R., UÇAR, M. (2022). The Effect of Low FT3 Level on Kidney Disease Progression and Potassium Levels in Euthyroid Adult Patients with Solitary Kidney. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 26 - Sayı: 1, 86–92. https://ajindex.com/articles/636100

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Iglesias P, Díez JJ: Thyroid dysfunction and kidney disease. Eur J Endocrinol 2009;160:503-515
  2. Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G: Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1296-1300
  3. Tatar E, Isıkyakar T, Gungor O, Yeniay KP, Taslı F, Ok ES, Sen S, Demirci MS, Basci A: Low T3 Syndrome in adult patients with nephrotic syndrome. Turk Neph Dial Transpl 2014;23:137-141 4. Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS: The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant 2009; 24:1534-1538
  4. Ozen KP, Asci G, Gungor O, Carrero JJ, Kircelli F, Tatar E, Sevinc Ok E, Ozkahya M, Toz H, Cirit M, Basci A, Ok E: Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol 2011; 33:305-312
  5. Tatar E, Kircelli F, Ok E: The contribution of thyroid dysfunction on cardiovascular disease in patients with chronic kidney disease. Atherosclerosis. 2013;227:26-31
  6. Tatar E, Sezis Demirci M, Kircelli F, Gungor O, Yaprak M, Asci G, Basci A, Ozkahya M, Ok E: The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. Int Urol Nephrol. 2012;44:601-606
  7. Tatar E, Kircelli F, Asci G, Carrero JJ, Gungor O, Demirci MS, Ozbek SS, Ceylan N, Ozkahya M, Toz H, Ok E: Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2240-2246
  8. Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL, Segev DL: Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311:579-586
  9. Sanna-Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R, Piaggio G, Innocenti ML, Somenzi D, Trivelli A, Caridi G, Izzi C, Scolari F, Mattioli G, Allegri L, Ghiggeri GM: Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int. 2009;76:528-533
  10. Hosokawa Y, Tanaka N, Mibu H, Anai S, Torimoto K, Yoneda T, Hirayama A, Yoshida K, Hayashi Y, Hirao Y, Fujimoto K: Followup study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume. World J Surg Oncol. 2014;12:59
  11. Park CW, Shin YS, Ahn SJ, Kim SY, Choi EJ, Chang YS, Bang BK: Thyroxine treatment induces upregula